SCHEMBL5163090

SCHEMBL5163090

COc1ccc(CCn2c(-c3ccco3)nc3c(N)nc(NCCc4ccccc4)nc32)cc1

nearest known ligand 0.77

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ADORA2A P29274 16/20 0.77
ADORA1 P30542 14/20 0.77
ADORA2B P29275 13/20 0.77
TMIGD3 P0DMS9 5/20 0.77
ADORA3 P0DMS8 9/20 0.63
KDM4E B2RXH2 2/20 0.57
MEN1 O00255 2/20 0.57
ALDH1A1 P00352 2/20 0.57
HPGD P15428 2/20 0.57
KMT2A Q03164 2/20 0.57
CASP1 P29466 1/20 0.57
CASP7 P55210 1/20 0.57
HSD17B10 Q99714 1/20 0.57
TLR7 Q9NYK1 1/20 0.49
LMNA P02545 1/20 0.46
GLA P06280 1/20 0.46
GAA P10253 1/20 0.46
MAPT P10636 1/20 0.46
HTT P42858 1/20 0.46
ATM Q13315 1/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5362031 0.95 ADORA2A (0.78) ADORA2AADORA1ADORA2BTMIGD3ADORA3
SCHEMBL5359590 0.92 ADORA2A (0.87) ADORA2AADORA1ADORA2BTMIGD3ADORA3
SCHEMBL5163631 0.87 ADORA2A (1.00) ADORA2AADORA1ADORA2BTMIGD3ADORA3
SCHEMBL5160548 0.86 ADORA2A (0.88) ADORA2AADORA1ADORA2BTMIGD3ADORA3
SCHEMBL5161742 0.85 ADORA2A (0.85) ADORA2AADORA1ADORA2BTMIGD3ADORA3
SCHEMBL5162241 0.85 ADORA2A (0.88) ADORA2AADORA1ADORA2BTMIGD3ADORA3
SCHEMBL5161655 0.84 ADORA2A (0.86) ADORA2AADORA1ADORA2BTMIGD3ADORA3
SCHEMBL5191357 0.83 KDM4E (0.58) ADORA2AADORA1ADORA2BTMIGD3ADORA3
SCHEMBL5351466 0.83 KDM4E (0.60) ADORA2AADORA1ADORA2BTMIGD3ADORA3
SCHEMBL5164662 0.83 ADORA2A (0.78) ADORA2AADORA1ADORA2BTMIGD3ADORA3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7189730-B2 A2A adenosine receptor antagonists CV THERAPEUTICS, INC. (US) 2007-03-13 US disclosed
EP-1456209-B1 A2A ADENOSINE RECEPTOR ANTAGONISTS CV THERAPEUTICS INC (US) 2007-02-28 EP disclosed
US-20030149060-A1 A2A adenosine receptor antagonists CV THERAPEUTICS, INC. 2003-08-07 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030149060-A1 A2A adenosine receptor antagonists ADORA2A, ADORA2B, ADORA3 ADORA2A 1/4885ADORA1 4/4885ADORA2B 2/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.